EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU(TM) for Treatment of Wet Age-Related Macular Degeneration

Stock Information for Milestone Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Milestone Pharmaceuticals Inc.

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint Announces Participation at Upcoming Investor Conferences
EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.